Genmab extends its activities  

Genmab branches into infectious diseases through alliance with ACE BioSciences
Financial daily Børsen reports that Genmab has formed an alliance with the Fyn-based biotech company ACE BioSciences to develop new antibody therapeutic products for the treatment of infectious diseases. This marks an extension of Genmab's activities which have so far been focused on inflammatory diseases and cancer. The two companies will share the development costs and revenues generated from sales or out-licensing of potential products. Genmab, an offshoot of the US company Medarex, is currently building a DKK 125 million (USD 15 million) factory in Medicon Valley north of Copenhagen, which is planned to open by the end of 2004. ACE Biosciences, part of the internationally renowned biotech cluster in Odense, specialises in mapping protein communication networks in pathogenic microorganisms with the aim of finding new treatments for infectious diseases.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×